Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Valeant Pharmaceuticals International Inc (NYSE:VRX)

16.54
Delayed Data
As of Nov 22
 +0.55 / +3.44%
Today’s Change
8.31
Today|||52-Week Range
18.65
+13.91%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Pharmaceuticals: Other
MARKET CAP
$5.7B

Company Description

Valeant Pharmaceuticals International, Inc. engages in the development, manufacture, and market of a broad range of pharmaceutical products in the areas of dermatology, gastrointestinal disorders, eye health, neurology and branded generics. It operates through the following segments: The Bausch + Lomb/International, The Branded Rx, and The U.S. Diversified products. The Bausch + Lomb/International segment is consist of the sale of pharmaceutical products, over-the-counter products, and medical devices products. The Branded Rx segment is comprised of pharmaceutical products related to the Salix product portfolio; dermatological product portfolio; branded pharmaceutical products, branded generic pharmaceutical products; over-the-counter products; medical device products; Bausch + Lomb products sold in Canada; and the oncology, dentistry, and health products for women. The U.S. Diversified Products segment is the sales in the U.S. of pharmaceutical products, over-the-counter products, and medical device products in the areas of neurology and certain other therapeutics classes, including aesthetics and generic products in the U.S. The company was founded on March 29, 1994 and is headquartered in Laval, Canada.

Contact Information

Valeant Pharmaceuticals International, Inc.
2150, St. Elzéar boulevard Ouest
Laval Qubec H7L 4A8
P:(800) 361-1448
Investor Relations:
(905) 695-7607

Employees

Shareholders

Other institutional37.28%
Individual stakeholders14.27%
Mutual fund holders14.07%

Top Executives

Joseph C. PapaChairman & Chief Executive Officer
Paul S. HerendeenChief Financial Officer & Executive VP-Finance
Tage RamakrishnaChief Medical Officer, President-R&D
Christina M. AckermannExecutive Vice President & General Counsel
Sam EldessoukyChief Accounting Officer, Senior VP & Controller